Recursion Pharmaceuticals today announced it will be participating in the White House’s Precision Medicine Initiative. Recursion will join researchers from Harvard Medical School, the University of Utah, Boston Children’s Hospital, and Pairnomix LLC, to form the Patient-Empowered Precision Medicine Alliance (PEPMA) in response to President Obama’s call to create personalized medical treatments at significantly reduced cost. This announcement coincides with Vice President Joe Biden’s visit tomorrow to the Huntsman Cancer Institute at the University of Utah in support of the Precision Medicine Initiative (PMI).
PEPMA’s goal is to target ultra-rare genetic disorders in a 12-month time-frame and quickly match patients to extremely specific treatments as efficiently as possible. Recursion’s high-throughput analysis platform will provide data to precisely model the effect of treatments at a genetic level, contributing the quick analysis that is vital to the success of personalized medicine.
”We have built a platform to enable drug discovery at scale across hundreds of genetic diseases, and this initiative is no different,” said Chris Gibson, Ph.D., Co-Founder, and CEO of Recursion. “Whether a genetic disease affects 1 person or 1 million people, our platform can be efficiently leveraged to quickly find new ways to use known drugs or other rapidly translatable compounds as potential treatments.”
The PMI seeks to increase partnering between private and public sector researchers in order to capitalize on emerging technologies. Recursion’s cutting-edge approach, paired with the experience of its partners in PEPMA, has the transformational potential to drive this research. The White House’s support of revolutionizing medical diagnosis and treatment has created a unique moment for the medical community to take an important leap forward.
“The power of precision medicine is not simply to apply top line technologies to previously unsolvable medical problems, but to create the most cost effective solutions for our patient populations who disproportionately need healthcare resources,” said Dean Li, MD, Ph.D., CSO of Recursion and Vice Dean of Research for the University of Utah. “The most valuable precision medicine strategies keep in focus population health strategies—this is how the University of Utah views its charge and this is what Recursion Pharmaceutical seeks to apply to drug discovery and development at scale.”
A spin-out of the University of Utah, Recursion is particularly well prepared to contribute to precision medicine, as the company had its genesis in the concept that data science and biological science could be combined to identify drug matches more quickly than is possible with a traditional “one drug, one disease” approach. The Precision Medicine Initiative offers the opportunity for Recursion to partner with other top-tier researchers to demonstrate the way in which the healthcare industry must evolve to incorporate innovative technologies.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, artificial intelligence, machine learning, and in vivo validation capabilities with a highly cross-functional team to discover novel medicines and expand our collective understanding of biology. Recursion’s rich, relatable database of 4 petabytes of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. Recursion is proudly headquartered in Salt Lake City. Learn more at www.recursionpharma.com or connect on www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.